CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

NCT07019363 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1903

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Adjuvant Therapy

Interventions

DRUG: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
DRUG: Standard endocrine therapy combined with CDK4/6 Inhibitor

Sponsor

Fudan University